Formulation and evaluation of pioglitazone sustained release matrix tablets

Abstract

The aim of the present work is to Formulate and Evaluate sustained release of Pioglitazone matrix tablets used for

treatment of diabetes mellitus. Development of SR Pioglitazone is proposed considering the adverse event profile

and high fluctuation index of Pioglitazone observed with SR dosage forms. In the present work, attempts were made

to formulate and evaluate sustained release of matrix tablets of Pioglitazone. Pioglitazone was subjected to

preformulation studies, based on the results obtained Pioglitazone sustained release tablets were successfully

formulated. Formulations prepared by direct compression technique using various polymers. Set of trials were

formulated for which Pioglitazone evaluated parameters (bulk density, tapped density, compressibility index,

hausner’s ratio, weight, thickness, hardness) were found to lie within the specifications. Dissolution study was

performed in USP type II apparatus at 100 RPM in pH 6. 8 phosphate buffer. From the results of the invitro study it

appears that the release of the Pioglitazone was significantly influenced by the characteristics of the polymer used.